Data to be presented at the 2022 AACR annual meeting highlights the unique nature of post-chemotherapy derived gene expression signatures in stratifying patient outcomes
The findings support the fact that further extension of nationwide cardiovascular disease (CVD) risk identification programs and prevention strategies to reduce the occurrence of cardiovascular diseases are warranted
Yashoda Hospitals Hyderabad has earned the distinction of becoming the first to introduce BTVA in India
Ondexxya is the first approved reversal agent specifically for Factor Xa inhibitors, providing a major advance in the treatment of patients hospitalised with life-threatening bleeding
The registry will be conducted for approximately two and a half years and up to 200 subjects will be enrolled
In May 2021, Daiichi Sankyo had submitted a supplemental new drug application (sNDA) for Tarlige tablets based on results from a phase 3 trial in patients with CNP
Clinical improvements were consistent across patient subgroups including age, gender, ethnicity, and IL-36 gene mutation status
First PARP inhibitor to demonstrate overall survival benefit in early breast cancer
New results build on previously reported significant recurrence-free survival (rfs) benefit seen in these patients
Since the beginning of the pandemic, more than one million patients with severe COVID-19 have been treated with Actemra/RoActemra
Subscribe To Our Newsletter & Stay Updated
